Patents Assigned to Tapestry Pharmaceuticals, Inc.
-
Patent number: 11873308Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: December 1, 2021Date of Patent: January 16, 2024Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Patent number: 11786504Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: September 9, 2021Date of Patent: October 17, 2023Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 11220512Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: July 15, 2020Date of Patent: January 11, 2022Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Publication number: 20210401797Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: September 9, 2021Publication date: December 30, 2021Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. MCCHESNEY, Gilles H. TAPOLSKY, David L. EMERSON, John MARSHALL, Michael KURMAN, Manuel MODIANO
-
Patent number: 11147793Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: October 12, 2018Date of Patent: October 19, 2021Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 10745408Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: September 12, 2019Date of Patent: August 18, 2020Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Patent number: 10639293Abstract: The present invention relates to a method for the treatment of cancer in a cancer patient.Type: GrantFiled: January 14, 2019Date of Patent: May 5, 2020Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Patent number: 10450323Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: October 30, 2017Date of Patent: October 22, 2019Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Patent number: 10238621Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.Type: GrantFiled: October 9, 2017Date of Patent: March 26, 2019Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Publication number: 20190046501Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: October 12, 2018Publication date: February 14, 2019Applicant: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 10143677Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: April 10, 2017Date of Patent: December 4, 2018Assignee: TAPESTRY PHARMACEUTICALS, INC.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20180117002Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: April 10, 2017Publication date: May 3, 2018Applicant: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9820962Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.Type: GrantFiled: July 27, 2016Date of Patent: November 21, 2017Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Patent number: 9802951Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: July 25, 2013Date of Patent: October 31, 2017Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Publication number: 20170273942Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: April 10, 2017Publication date: September 28, 2017Applicant: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9616043Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: September 11, 2015Date of Patent: April 11, 2017Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9402824Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.Type: GrantFiled: January 23, 2015Date of Patent: August 2, 2016Assignee: Tapestry Pharmaceuticals, Inc.Inventors: Jan Zygmunt, James Ferrara, James D. McChesney
-
Publication number: 20160113898Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: ApplicationFiled: September 11, 2015Publication date: April 28, 2016Applicant: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Patent number: 9132118Abstract: Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.Type: GrantFiled: March 5, 2013Date of Patent: September 15, 2015Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles Tapolsky, David L. Emerson, John Marshall, Michael Kurman, Manuel Modiano
-
Publication number: 20150133536Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G? or Formula M?: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.Type: ApplicationFiled: January 23, 2015Publication date: May 14, 2015Applicant: Tapestry Pharmaceuticals, Inc.Inventors: Jan ZYGMUNT, James FERRARA, James D. MCCHESNEY